SGN CD123A

Drug Profile

SGN CD123A

Alternative Names: SGN CD123A

Latest Information Update: 20 Sep 2016

Price : $50

At a glance

  • Originator Seattle Genetics
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA cross linking agents; Interleukin-3-receptor-alpha-subunit-antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Acute myeloid leukaemia

Most Recent Events

  • 01 Aug 2016 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in USA (IV) (NCT02848248)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top